Pharmaceuticals Give Large Sums of Money to Physicians

Most patients are unaware that different pharmaceutical companies give doctors thousands of dollars for each patient that they enrol in experimental drug trials.

Even though the motive’s of the doctor’s may be pure and the medications are what is best for the patient’s sickness, patients need to be know about such payments to discuss them with the doctor and then decided for themselves if the participation by the doctor in the trial might cause his medical advice to be compromised.

The healthcare reform legislation has a provision that should bring transparency about the payments to doctors and other corporate benefits physicians receive. Included in those benefits are gifts, lavish dinners and conventions sponsored by pharmaceutical companies that are more of a luxury vacation than medical convention. The new provision will publish all the information in a database online.

The final regulations were supposed to be completed and published in October of 2011, with the database going live sometime during 2013. However, the regulations needed are over 15 months late.

Just as with the regulations for the food-safety act, most of the final regulations for this act have been help up in the Office of Management and Budget after being written up by an appropriate agency. On thought over the delay is President Obama did not want to issue the regulations prior to the election, when the healthcare reform law was a contentious issue with voters.

Most doctors put the well-being of their patients first, but a recent study has shown that physicians who are given food from a company are more apt to prescribe the products from that company, even though the doctor might not consciously being doing it.

 

Latest News

Retail Opportunity Investments Corp  Expected to Announce Earnings of $0.29 Per Share
Retail Opportunity Investments Corp Expected to Announce Earnings of $0.29 Per Share
Andeavor Logistics LP  Receives $50.67 Consensus Target Price from Analysts
Andeavor Logistics LP Receives $50.67 Consensus Target Price from Analysts
Somewhat Positive Media Coverage Somewhat Unlikely to Impact Gemphire Therapeutics  Stock Price
Somewhat Positive Media Coverage Somewhat Unlikely to Impact Gemphire Therapeutics Stock Price
Aviat Networks  Given Daily Media Impact Rating of 0.09
Aviat Networks Given Daily Media Impact Rating of 0.09
Papa Murphy’s  Getting Somewhat Positive News Coverage, Report Shows
Papa Murphy’s Getting Somewhat Positive News Coverage, Report Shows
EXFO  Given Average Recommendation of “Hold” by Brokerages
EXFO Given Average Recommendation of “Hold” by Brokerages


© 2006-2018 Ticker Report. Google+.